IsoRay to produce Proxcelan in Richland
Radioisotope manufacturer IsoRay Medical said that it plans to transfer production of its Proxcelan brand of Cesium-131 brachytherapy seeds to expanded facilities 75 days ahead of schedule.
The facility is located at Energy Northwest’s Applied Process Engineering Laboratory in Richland, Wash.
The company said the expansion is one element in its strategy to expand production of Proxcelan (Cesium-131) brachytherapy seeds as well as develop other medical isotopes to treat cancer and other diseases.
The 15,340-square-foot expansion brings the total production space to approximately 20,000 square feet, consolidating IsoRay’s current U.S. operations into a single location. It will allow IsoRay to more than double its seed production capacity to approximately 100,000 seeds per month, the company said.
The facility is located at Energy Northwest’s Applied Process Engineering Laboratory in Richland, Wash.
The company said the expansion is one element in its strategy to expand production of Proxcelan (Cesium-131) brachytherapy seeds as well as develop other medical isotopes to treat cancer and other diseases.
The 15,340-square-foot expansion brings the total production space to approximately 20,000 square feet, consolidating IsoRay’s current U.S. operations into a single location. It will allow IsoRay to more than double its seed production capacity to approximately 100,000 seeds per month, the company said.